Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => 7期肝癌的诊断和治疗 => 肝脏肿瘤 =>
Clinic Liver Cancer stage C primary liver cancer and related prognostic factors: An analysis of 140 cases
文章发布日期:2018年06月07日  来源:  作者:郭晓笛,孙莎莎,李文东,等  点击次数:757次  下载次数:100次
Adjust font size:Small regular big

【Abstract】:Objective To investigate the clinical features of patients with Barcelona Clinic Liver Cancer (BCLC) stage C primary liver cancer(PLC) and related prognostic factors. Methods A retrospective analysis was performed for the clinical data of 140 patients with BCLC stage C PLC who were admitted to Beijing Ditan Hospital, Capital Medical University, from October 2008 to December 2015. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used for univariate analysis. The multivariate Cox proportional hazards model was used to analyze prognostic factors according to forward stepwise regression based on maximum likelihood estimation. Results Most of the 140 patients were male, and the male/female ratio was 6∶1. The three most common initial symptoms of PLC were abdominal pain or liver area pain, weakness, and abdominal distension. The median survival time was 6 months, and the median follow-up time was 10 months (1-80 months). The 1-year survival rate of these patients was 22.14%. The univariate analysis showed that Child-Pugh class, the type of portal vein tumor thrombus, tumor number, tumor morphology, tumor diameter, aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, and use or non-use of transcatheter arterial chemoembolization (TACE) were associated with prognosis (χ2=6.215, 19.609, 8.849, 11.122, 11.571, 7.438, 30.511, and 10.690, all P<0.05). The multivariate analysis showed that Child-Pugh class (odds ratio [OR]=1.524, 95% confidence interval [CI]: 1.011-2.297, P=0.044), tumor diameter (OR=1.803, 95%CI: 1.097-2.964, P=0.020), and AST/ALT ratio (OR=1.769, 95%CI: 1.301-2.406, P<0.001) were independent risk factors for the prognosis of advanced PLC, while the use of TACE was a protective factor (OR=0.598, 95%CI: 0.363-0.985, P=0.043). Conclusion Advanced PLC has poor prognosis and short median survival time. A more accurate survival benefit analysis should be performed based on adverse prognostic factors to guide the selection of therapeutic paradigms in clinical practice. Increased AST/ALT ratio should also be taken seriously.
【Key words】:liver neoplasms; disease attributes; prognosis; risk factors

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号